Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardiacAssist gets US OK for TandemHeart PTVA (percutaneous transseptal ventricular assist) technology:

This article was originally published in Clinica

Executive Summary

CardiacAssist can now market in the US its TandemHeart percutaneous transseptal ventricular assist (PTVA) system for short-term circulatory support, after gaining FDA 510(k) clearance for the product's final component: the transseptal cannula. The TandemHeart PTVA device was previously CE-marked for sale in Europe in 2000. It can be used to support critically ill patients with heart failure and cardiogenic shock. The system is currently being compared with conventional intra aortic balloon pump therapy in a cardiogenic shock trial in the US, says the Pittsburgh, Pennsylvania firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT062521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel